AIM ImmunoTech Valuation

Is HXB2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HXB2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HXB2's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HXB2's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for HXB2?

Key metric: As HXB2 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for HXB2. This is calculated by dividing HXB2's market cap by their current book value.
What is HXB2's PB Ratio?
PB Ratio4.9x
BookUS$2.91m
Market CapUS$14.33m

Price to Book Ratio vs Peers

How does HXB2's PB Ratio compare to its peers?

The above table shows the PB ratio for HXB2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.5x
CNW co.don
1xn/a€6.5m
MDG1 Medigene
1x11.0%€20.6m
HPHA Heidelberg Pharma
3x-33.0%€106.7m
2INV 2invest
1xn/a€63.2m
HXB2 AIM ImmunoTech
4.9x-0.3%€14.3m

Price-To-Book vs Peers: HXB2 is expensive based on its Price-To-Book Ratio (4.9x) compared to the peer average (1.7x).


Price to Book Ratio vs Industry

How does HXB2's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
HXB2 4.9xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: HXB2 is expensive based on its Price-To-Book Ratio (4.9x) compared to the European Biotechs industry average (2.4x).


Price to Book Ratio vs Fair Ratio

What is HXB2's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HXB2 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate HXB2's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HXB2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.17
€2.88
+1,584.7%
66.7%€4.80€0.96n/a2
Nov ’25€0.22
€2.93
+1,207.2%
52.1%€4.62€0.92n/a3
Oct ’25€0.19
€3.17
+1,584.5%
35.0%€4.52€1.81n/a3
Sep ’25€0.27
€3.17
+1,072.9%
35.0%€4.52€1.81n/a3
Aug ’25€0.28
€3.30
+1,079.6%
37.1%€4.84€1.84n/a3
Jul ’25€0.30
€3.30
+1,000.9%
37.1%€4.84€1.84n/a3
Jun ’25€0.30
€3.30
+1,015.8%
37.1%€4.84€1.84n/a3
May ’25€0.35
€3.28
+847.6%
35.0%€4.68€1.87n/a3
Apr ’25€0.44
€2.53
+471.5%
27.3%€3.21€1.84n/a2
Mar ’25€0.33
€3.50
+961.5%
43.0%€5.48€1.83n/a3
Feb ’25€0.36
€3.50
+884.0%
43.0%€5.48€1.83n/a3
Jan ’25€0.43
€3.50
+710.9%
43.0%€5.48€1.83n/a3
Dec ’24€0.39
€3.50
+789.1%
43.0%€5.48€1.83n/a3
Nov ’24€0.42
€3.58
+759.5%
43.0%€5.60€1.87€0.223
Oct ’24€0.39
€3.58
+816.8%
43.0%€5.60€1.87€0.193
Sep ’24€0.57
€3.59
+524.7%
44.9%€5.73€1.83€0.273
Aug ’24€0.57
€3.66
+543.0%
44.9%€5.85€1.87€0.283
Jul ’24€0.60
€3.66
+505.8%
44.9%€5.85€1.87€0.303
Jun ’24€0.38
€3.66
+869.5%
44.9%€5.85€1.87€0.303
May ’24€0.44
€4.89
+1,022.0%
30.9%€5.96€2.75€0.353
Apr ’24€0.34
€5.20
+1,431.7%
31.6%€6.48€2.88€0.443
Mar ’24€0.48
€5.20
+977.9%
31.6%€6.48€2.88€0.333
Feb ’24€0.49
€5.20
+959.7%
31.6%€6.48€2.88€0.363
Jan ’24€0.28
€5.20
+1,765.6%
31.6%€6.48€2.88€0.433
Dec ’23€0.37
€5.20
+1,289.4%
31.6%€6.48€2.88€0.393
Nov ’23€0.58
€5.52
+849.7%
33.2%€7.17€2.97€0.423

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies